CMS To Increase Drug Price Transparency

The Trump Administration has finalized adjustments to Medicare Advantage and Medicare Part D to ensure patients have greater transparency in the cost of prescription drugs, along with improved visibility to their options.

Under this new rule, the Explanation of Benefits document that Part D enrollees receive should now include notice of drug price increases as well as lower-cost alternatives.

For more on this, please see the CMS press release below.

Leave a Comment